What is Kaleo?
Founded in 2005, Kaleo operates as a specialized pharmaceutical company dedicated to the development and manufacturing of innovative medical solutions. By focusing on high-impact therapeutic areas, the company has carved out a distinct market position that bridges the gap between complex drug delivery systems and patient-centric care. Its headquarters in Richmond, Virginia, serves as the hub for its research, development, and commercialization efforts, allowing the firm to maintain a competitive edge in the highly regulated pharmaceutical landscape. The company's growth trajectory is characterized by a disciplined approach to debt financing, which has enabled it to scale its manufacturing infrastructure while maintaining operational independence.
How much funding has Kaleo raised?
Kaleo has raised a total of $165M across 2 funding rounds:
Debt
$15M
Debt
$150M
Debt (2012): $15M with participation from Hercules Technology Growth Capital
Debt (2014): $150M led by PDL BioPharma
Key Investors in Kaleo
Hercules Technology Growth Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries.
PDL BioPharma
PDL BioPharma manages a portfolio of patents and royalty assets, consisting of license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired.
What's next for Kaleo?
With the recent infusion of capital, Kaleo is well-positioned to accelerate its product pipeline and expand its market reach. The strategic allocation of these funds will likely focus on enhancing manufacturing efficiencies and supporting the commercial rollout of its core pharmaceutical portfolio. As the company moves into its next phase of development, the focus will remain on navigating the complexities of the healthcare market, leveraging its existing intellectual property, and exploring new therapeutic applications. The firm's ability to attract institutional debt financing suggests a high level of confidence from its financial partners in the company's long-term viability and its capacity to deliver sustained value in the pharmaceutical industry.
See full Kaleo company page
